(Q36084891)

English

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Safety, pharmacokinetics, and biologic activity of pateclizumab, a novel monoclonal antibody targeting lymphotoxin α: results of a phase I randomized, placebo-controlled trial (English)

1 reference

Europe PubMed Central

12 August 2017

phase I clinical trial

0 references

0 references

monoclonal antibody

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

author name string

Brinda Emu

1

1 reference

Europe PubMed Central

12 August 2017

Diana Luca

2

1 reference

Europe PubMed Central

12 August 2017

Carolyn Offutt

3

1 reference

Europe PubMed Central

12 August 2017

Jane L Grogan

4

1 reference

Europe PubMed Central

12 August 2017

Bernadette Rojkovich

5

1 reference

Europe PubMed Central

12 August 2017

Marna B Williams

6

1 reference

Europe PubMed Central

12 August 2017

Meina T Tang

7

1 reference

Europe PubMed Central

12 August 2017

Jim Xiao

8

1 reference

Europe PubMed Central

12 August 2017

June H Lee

9

1 reference

Europe PubMed Central

12 August 2017

John C Davis

10

1 reference

Europe PubMed Central

12 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

8 January 2012

1 reference

Europe PubMed Central

12 August 2017

Arthritis Research and Therapy

1 reference

Europe PubMed Central

12 August 2017

14

1 reference

Europe PubMed Central

12 August 2017

1

1 reference

Europe PubMed Central

12 August 2017

R6

1 reference

Europe PubMed Central

12 August 2017

https://scigraph.springernature.com/pub.10.1186/ar3554

0 references

The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Immunopathologic aspects of rheumatoid arthritis: who is the conductor and who plays the immunologic instrument?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

B cells in rheumatoid synovitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Network communications: lymphotoxins, LIGHT, and TNF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Lymphotoxin/light, lymphoid microenvironments and autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

2 October 2017

Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease

1 reference

https://api.crossref.org/works/10.1186%2FAR3554

21 January 2018

Comparison of interferon {gamma} release assays and conventional screening tests before tumour necrosis factor {alpha} blockade in patients with inflammatory arthritis.

1 reference

https://api.crossref.org/works/10.1186%2FAR3554

21 January 2018

CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3392792

23 September 2018

Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint

1 reference

https://api.crossref.org/works/10.1186%2FAR3554

21 January 2018

Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphoid neogenesis in rheumatoid synovitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphotoxin alphabeta is expressed on recently activated naive and Th1-like CD4 cells but is down-regulated by IL-4 during Th2 differentiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inflammation and ectopic lymphoid structures in rheumatoid arthritis synovial tissues dissected by genomics technology: identification of the interleukin-7 signaling pathway in tissues with lymphoid neogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lymphotoxin-alphabeta heterotrimers are cleaved by metalloproteinases and contribute to synovitis in rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/22225620

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

1 reference

Europe PubMed Central

12 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36084891&oldid=2143782985"